Influenza
A viruses possess a high antigenic shift, and the approved
anti-influenza drugs are extremely limited, which makes the development
of novel anti-influenza drugs for the clinical treatment and prevention
of influenza outbreaks imperative. Herein, we report a series of novel
aryl benzoyl hydrazide analogs as potent anti-influenza agents. Particularly,
analogs 10b, 10c, 10g, 11p, and 11q exhibited potent inhibitory activity
against the avian H5N1 flu strain with EC50 values ranging
from 0.009 to 0.034 μM. Moreover, compound 11q exhibited
nanomolar antiviral effects against both the H1N1 virus and Flu B
virus and possessed good oral bioavailability and inhibitory activity
against influenza A virus in a mouse model. Preliminary mechanistic
studies suggested that these compounds exert anti-influenza virus
effects mainly by interacting with the PB1 subunit of RNA-dependent
RNA polymerase (RdRp). These results revealed that 11q has the potential to become a potent clinical candidate to combat
seasonal influenza and influenza pandemics.
In this study, we reported the synthesis and biological characterization of a novel series of furancarboxamide derivatives that were potent inhibitors of the influenza A H5N1 virus. The systematic structure-activity relationship (SAR) studies demonstrated that the 2,5-dimethyl-substituted heterocyclic moiety (furan or thiophene) had significant influence on the anti-influenza activity. In particular, 2,5dimethyl-N-(2-((4-nitrobenzyl)thio)ethyl)-furan-3-carboxamide 1a showed the best activity against the H5N1 virus with an EC 50 value of 1.25 mM. For the first time, the simple scaffold furan-carboxamide derivatives were identified as novel inhibitors of lethal H5N1 influenza A virus. † Electronic supplementary information (ESI) available: NMR spectra of nal compounds 1a-1v. See
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.